Multiple Myeloma Coverage from Every Angle

Recent News

Left Ventricular Diastolic Function and Carfilzomib-Induced Cardiovascular Events
Moving Mountains for Multiple Myeloma: Hiking Through Iceland
Does Depression Affect Survival Outcomes in Patients With Multiple Myeloma?
Treatment Outcomes for Patients With t(11;14) Translocation Multiple Myeloma
Subcutaneous Versus Intravenous Daratumumab in Resistant Multiple Myeloma
Novel Monoclonal Antibody Under Study in Resistant Multiple Myeloma
Updated ELOQUENT Data Support Elotuzumab Combination Regimen in Myeloma
Autologous Stem Cell Transplantation: Patient and Caregiver Quality of Life
FDA Accepts Biologics License Application for Isatuximab in Resistant Multiple Myeloma
EHA24 Congress: Selinexor With Daratumumab and Dexamethasone in Resistant Myeloma
FDA Grants Accelerated Approval to Selinexor Combination for Resistant Myeloma
Addition of Isatuximab to Pomalidomide/Dexamethasone in Multiple Myeloma
Partial Clinical Hold Lifted by FDA on Venetoclax Study in Multiple Myeloma
FDA Approves Daratumumab Combination for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma
EHA24 Congress: Melflufen Combination Regimen for Resistant Multiple Myeloma
ICML 2019: Is Triplet Induction Therapy Safe for Older Patients With Multiple Myeloma?
EHA24 Congress: Novel Agent Under Study in Combination Therapies for Myeloma
EHA24 Congress: Daratumumab Plus Standard Therapy in Newly Diagnosed Myeloma
EHA24 Congress: Venetoclax Combination Therapy in Resistant Myeloma
ASCO 2019: Adding Daratumumab to Standard of Care in Transplant-Eligible Newly Diagnosed Myeloma
Daratumumab Combination Therapy Granted Priority Review in Multiple Myeloma
ASCO 2019: Predicting Early Relapse in Patients With Myeloma Treated With Triplet Regimens
ASCO 2019: Impact of Insurance Type on Survival in Multiple Myeloma
ECT-001 Granted Regenerative Medicine Advanced Therapy Designation for Treatment of Hematologic Malignancies
Evaluating Adherence to Immunomodulatory Drugs in Multiple Myeloma
FDA Grants Fast Track Designation for CLR 131 in Multiple Myeloma
ASCO 2019: Lenalidomide vs. Observation in Smoldering Multiple Myeloma
Immunoglobulin Lambda Translocation and Treatment Resistance in Multiple Myeloma
Multiple Myeloma Research Foundation Launches Investment Fund to Advance New Therapies
Novel Selective HDAC6 Inhibitor Under Study in Multiple Myeloma
Severe Obesity and Outcomes After Transplant for Myeloma
Allogeneic CAR T-Cell Therapy to Enter Phase I Trial in Multiple Myeloma
Role of Mesenchymal Stem Cells in Progression of Multiple Myeloma
FDA Warns of Risks Associated With Investigational Use of Venetoclax in Multiple Myeloma
Real-World Findings With Ixazomib, Lenalidomide, and Dexamethasone in Multiple Myeloma
Modeling Renal Injury in Multiple Myeloma
Challenges in Precision Medicine Strategies in Multiple Myeloma
Perlmutter Cancer Center Receives Anonymous Gift of $75 Million for New Blood Cancer Center

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.